Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase II research study that is designed for patients who have small cell lung
cancer (SCLC) that is no longer responding to treatment. Patients will receive picoplatin, a
new platinum-based agent that is currently under investigation, in 21-day cycles.